Journal article
Capecitabine/irinotecan in colorectal cancer: European early-phase data and planned trials.
- Abstract:
-
Capecitabine (Xeloda) and irinotecan (CPT-11, Camptosar) exhibit single-agent activity in colorectal cancer, have nonoverlapping major toxicities, and exhibit a synergistic effect in tumor xenograft models. European early-phase trials of the combination in patients with metastatic colorectal cancer indicate good response rates across doses tested and manageable toxicities, with available data supporting use of a regimen of oral capecitabine at 1,000 mg/m2 twice daily on days 1 to 14 plus IV i...
Expand abstract
Actions
Authors
Bibliographic Details
- Journal:
- Oncology (Williston Park, N.Y.)
- Volume:
- 16
- Issue:
- 12 Suppl No 14
- Pages:
- 12-15
- Publication date:
- 2002-12-01
- ISSN:
-
0890-9091
- Source identifiers:
-
246209
Item Description
- Language:
- English
- Keywords:
- Pubs id:
-
pubs:246209
- UUID:
-
uuid:1d7b27e9-f4ed-42d6-af6d-f27b911a3bb3
- Local pid:
- pubs:246209
- Deposit date:
- 2012-12-19
Terms of use
- Copyright date:
- 2002
If you are the owner of this record, you can report an update to it here: Report update to this record